

AMENDMENTS TO LB 844

(Amendments to E & R amendments, ER8180)

Introduced by McDonald, 41.

1           1. Insert the following new section:

2           Section 1. Section 28-405, Revised Statutes Supplement,  
3 2007, is amended to read:

4           28-405 The following are the schedules of controlled  
5 substances referred to in the Uniform Controlled Substances Act:

6           Schedule I

7           (a) Any of the following opiates, including their  
8 isomers, esters, ethers, salts, and salts of isomers, esters, and  
9 ethers, unless specifically excepted, whenever the existence of  
10 such isomers, esters, ethers, and salts is possible within the  
11 specific chemical designation:

12           (1) Acetylmethadol;

13           (2) Allylprodine;

14           (3) Alphacetylmethadol, except levo-alphacetylmethadol  
15 which is also known as levo-alpha-acetylmethadol, levomethadyl  
16 acetate, and LAAM;

17           (4) Alphameprodine;

18           (5) Alphamethadol;

19           (6) Benzethidine;

20           (7) Betacetylmethadol;

21           (8) Betameprodine;

22           (9) Betamethadol;

- 1 (10) Betaprodine;
- 2 (11) Clonitazene;
- 3 (12) Dextromoramide;
- 4 (13) Difenoquin;
- 5 (14) Diampromide;
- 6 (15) Diethylthiambutene;
- 7 (16) Dimenoxadol;
- 8 (17) Dimepheptanol;
- 9 (18) Dimethylthiambutene;
- 10 (19) Dioxaphetyl butyrate;
- 11 (20) Dipipanone;
- 12 (21) Ethylmethylthiambutene;
- 13 (22) Etonitazene;
- 14 (23) Etozeridine;
- 15 (24) Furethidine;
- 16 (25) Hydroxypethidine;
- 17 (26) Ketobemidone;
- 18 (27) Levomoramide;
- 19 (28) Levophenacymorphan;
- 20 (29) Morpheridine;
- 21 (30) Noracymethadol;
- 22 (31) Norlevorphanol;
- 23 (32) Normethadone;
- 24 (33) Norpipanone;
- 25 (34) Phenadoxone;
- 26 (35) Phenampromide;
- 27 (36) Phenomorphan;

- 1 (37) Phenoperidine;
- 2 (38) Piritramide;
- 3 (39) Proheptazine;
- 4 (40) Properidine;
- 5 (41) Propiram;
- 6 (42) Racemoramide;
- 7 (43) Trimeperidine;
- 8 (44) Alpha-methylfentanyl,  
9 N-(1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl) propionanilide,  
10 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine;
- 11 (45) Tilidine;
- 12 (46) 3-Methylfentanyl,  
13 N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-phenylpropanamide, its  
14 optical and geometric isomers, salts, and salts of isomers;
- 15 (47) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its  
16 optical isomers, salts, and salts of isomers;
- 17 (48) PEPAP  
18 (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine), its optical  
19 isomers, salts, and salts of isomers;
- 20 (49) Acetyl-alpha-methylfentanyl  
21 (N-(1-(1-methyl-2-phenethyl)-4-piperidinyl)-N-phenylacetamide), its  
22 optical isomers, salts, and salts of isomers;
- 23 (50) Alpha-methylthiofentanyl  
24 (N-(1-methyl-2-(2-thienyl)ethyl-4-piperidinyl)-N-phenylpropanamide),  
25 its optical isomers, salts, and salts of isomers;
- 26 (51) Benzylfentanyl  
27 (N-(1-benzyl-4-piperidyl)-N-phenylpropanamide), its optical

1 isomers, salts, and salts of isomers;

2 (52) Beta-hydroxyfentanyl (N-(1-(2-hydroxy-2-  
3 phenethyl)-4-piperidinyl)-N-phenylpropanamide), its optical  
4 isomers, salts, and salts of isomers;

5 (53) Beta-hydroxy-3-methylfentanyl (other name:  
6 N-(1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl)-N-  
7 phenylpropanamide), its optical and geometric isomers, salts, and  
8 salts of isomers;

9 (54) 3-methylthiofentanyl  
10 (N-(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl)-N-phenylpropanamide),  
11 its optical and geometric isomers, salts, and salts of isomers;

12 (55)  
13 N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide  
14 (thenylfentanyl), its optical isomers, salts, and salts of isomers;

15 (56) Thiofentanyl  
16 (N-phenyl-N-(1-(2-thienyl)ethyl-4-piperidinyl)-propanamide), its  
17 optical isomers, salts, and salts of isomers; and

18 (57) Para-fluorofentanyl  
19 (N-(4-fluorophenyl)-N-(1-(2-phenethyl)-4-piperidinyl)propanamide),  
20 its optical isomers, salts, and salts of isomers.

21 (b) Any of the following opium derivatives, their salts,  
22 isomers, and salts of isomers, unless specifically excepted,  
23 whenever the existence of such salts, isomers, and salts of  
24 isomers is possible within the specific chemical designation:

25 (1) Acetorphine;

26 (2) Acetyldihydrocodeine;

27 (3) Benzylmorphine;

- 1 (4) Codeine methylbromide;
- 2 (5) Codeine-N-Oxide;
- 3 (6) Cyprenorphine;
- 4 (7) Desomorphine;
- 5 (8) Dihydromorphine;
- 6 (9) Drotebanol;
- 7 (10) Etorphine, except hydrochloride salt;
- 8 (11) Heroin;
- 9 (12) Hydromorphenol;
- 10 (13) Methyldesorphine;
- 11 (14) Methyldihydromorphine;
- 12 (15) Morphine methylbromide;
- 13 (16) Morphine methylsulfonate;
- 14 (17) Morphine-N-Oxide;
- 15 (18) Myrophine;
- 16 (19) Nicocodeine;
- 17 (20) Nicomorphine;
- 18 (21) Normorphine;
- 19 (22) Pholcodine; and
- 20 (23) Thebacon.
- 21 (c) Any material, compound, mixture, or preparation which
- 22 contains any quantity of the following hallucinogenic substances,
- 23 their salts, isomers, and salts of isomers, unless specifically
- 24 excepted, whenever the existence of such salts, isomers, and salts
- 25 of isomers is possible within the specific chemical designation,
- 26 and, for purposes of this subdivision only, isomer shall include
- 27 the optical, position, and geometric isomers:

1           (1) Bufotenine. Trade and other names shall include,  
2 but are not limited to: 3-(B-Dimethylaminoethyl)-5-hydroxyindole;  
3 3-(2-dimethylaminoethyl)-5-indolol;           N,N-dimethylserotonin;  
4 5-hydroxy-N,N-dimethyltryptamine; and mappine;

5           (2) Diethyltryptamine. Trade and other names shall  
6 include, but are not limited to: N,N-diethyltryptamine; and DET;

7           (3) Dimethyltryptamine. Trade and other names shall  
8 include, but are not limited to: DMT;

9           (4) 4-bromo-2,5-dimethoxyamphetamine. Trade and other  
10 names shall include, but are not limited to: 4-bromo-2,  
11 5-dimethoxy-a-methylphenethylamine; and 4-bromo-2,5-DMA;

12           (5) 4-methoxyamphetamine. Trade and other names shall  
13 include, but are not limited to: 4-methoxy-a-methyl-phenethylamine;  
14 and paramethoxyamphetamine, PMA;

15           (6) 4-methyl-2, 5-dimethoxyamphetamine. Trade  
16 and other names shall include, but are not limited to:  
17 4-methyl-2,5-dimethoxy-a-methylphenethylamine; DOM; and STP;

18           (7) 5-methoxy-N,N, dimethyltryptamine;

19           (8) Ibogaine. Trade and other names  
20 shall include, but are not limited to:  
21 7-ethyl-6,6B,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-  
22 pyrido (1',2':1,2) azepino (5,4-b) indole; and tabernanthe iboga;

23           (9) Lysergic acid diethylamide;

24           (10) Marijuana;

25           (11) Mescaline;

26           (12) Peyote. Peyote shall mean all parts of the plant  
27 presently classified botanically as *Lophophora williamsii* Lemaire,

1 whether growing or not, the seeds thereof, any extract from  
2 any part of such plant, and every compound, manufacture, salts,  
3 derivative, mixture, or preparation of such plant or its seeds or  
4 extracts;

5 (13) Psilocybin;

6 (14) Psilocyn;

7 (15) Tetrahydrocannabinols, including, but not limited  
8 to, synthetic equivalents of the substances contained in the plant  
9 or in the resinous extractives of cannabis, sp. or synthetic  
10 substances, derivatives, and their isomers with similar chemical  
11 structure and pharmacological activity such as the following: Delta  
12 1 cis or trans tetrahydrocannabinol and their optical isomers,  
13 excluding dronabinol in sesame oil and encapsulated in a soft  
14 gelatin capsule in a drug product approved by the federal Food  
15 and Drug Administration; Delta 6 cis or trans tetrahydrocannabinol  
16 and their optical isomers; and Delta 3,4 cis or trans  
17 tetrahydrocannabinol and its optical isomers. Since nomenclature  
18 of these substances is not internationally standardized, compounds  
19 of these structures shall be included regardless of the numerical  
20 designation of atomic positions covered;

21 (16) 3,4-methylenedioxy amphetamine;

22 (17) 5-methoxy-3,4-methylenedioxy amphetamine;

23 (18) 3,4,5-trimethoxy amphetamine;

24 (19) N-ethyl-3-piperidyl benzilate;

25 (20) N-methyl-3-piperidyl benzilate;

26 (21) Thiophene analog of phencyclidine. Trade  
27 and other names shall include, but are not limited to:

1 1-(1-(2-thienyl)-cyclohexyl)-piperidine; 2-thienyl analog of  
2 phencyclidine; TCP; and TCP;

3 (22) 2,5-dimethoxyamphetamine. Trade and  
4 other names shall include, but are not limited to:  
5 2,5-dimethoxy- $\alpha$ -methylphenethylamine; and 2,5-DMA;

6 (23) Hashish or concentrated cannabis;

7 (24) Parahexyl. Trade and other names shall include,  
8 but are not limited to: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,  
9 9-trimethyl-6H-dibenzo(b,d)pyran; and synhexyl;

10 (25) Ethylamine analog of phencyclidine. Trade  
11 and other names shall include, but are not limited to:  
12 N-ethyl-1-phenylcyclohexylamine; (1-phenylcyclohexyl)ethylamine;  
13 N-(1-phenylcyclohexyl)ethylamine; cyclohexamine; and PCE;

14 (26) Pyrrolidine analog of phencyclidine. Trade  
15 and other names shall include, but are not limited to:  
16 1-(1-phenylcyclohexyl)-pyrrolidine; PCPy; and PHP;

17 (27) 3,4-methylenedioxymethamphetamine (MDMA), its  
18 optical, positional, and geometric isomers, salts, and salts of  
19 isomers;

20 (28) 4-bromo-2,5-dimethoxyphenethylamine. Some trade  
21 or other names: 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane;  
22  $\alpha$ -desmethyl DOB; 2C-B; and Nexus;

23 (29) Alpha-ethyltryptamine. Some trade or other  
24 names: etryptamine; Monase;  $\alpha$ -ethyl-1H-indole-3-ethanamine;  
25 3-(2-aminobutyl) indole;  $\alpha$ -ET; and AET;

26 (30) 2,5-dimethoxy-4-ethylamphet-amine; and DOET;

27 (31) 1-(1-(2-thienyl)cyclohexyl)pyrrolidine; and TCPy;

1 (32) Alpha-methyltryptamine, which is also known as AMT;  
2 and

3 (33) 5-Methoxy-N, N-diisopropyltryptamine, which is also  
4 known as 5-MeO-DIPT;--

5 (34) Salvia divinorum. Salvia divinorum includes all  
6 parts of the plant presently classified botanically as Salvia  
7 divinorum, whether growing or not, the seeds thereof, any extract  
8 from any part of such plant, and every compound, manufacture,  
9 derivative, mixture, or preparation of such plant, its seeds,  
10 or its extracts, including salts, isomers, and salts of isomers  
11 whenever the existence of such salts, isomers, and salts of isomers  
12 is possible within the specific chemical designation; and

13 (35) Salvinorin A.

14 (d) Unless specifically excepted or unless listed in  
15 another schedule, any material, compound, mixture, or preparation  
16 which contains any quantity of the following substances having  
17 a depressant effect on the central nervous system, including its  
18 salts, isomers, and salts of isomers whenever the existence of  
19 such salts, isomers, and salts of isomers is possible within the  
20 specific chemical designation:

21 (1) Mecloqualone;

22 (2) Methaqualone; and

23 (3) Gamma-hydroxybutyric acid. Some other names include:  
24 GHB; gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-hydroxybutanoic  
25 acid; sodium oxybate; and sodium oxybutyrate.

26 (e) Unless specifically excepted or unless listed in  
27 another schedule, any material, compound, mixture, or preparation

1 which contains any quantity of the following substances having  
2 a stimulant effect on the central nervous system, including its  
3 salts, isomers, and salts of isomers:

4 (1) Fenethylline;

5 (2) N-ethylamphetamine;

6 (3) Aminorex; aminoxaphen; 2-amino-5-phenyl-2-oxazoline;  
7 and 4,5-dihydro-5-phenyl-2-oxazolamine;

8 (4) Cathinone; 2-amino-1-phenyl-1-propanone;  
9 alpha-aminopropiophenone; 2-aminopropiophenone; and norephedrone;

10 (5) Methcathinone, its salts, optical isomers,  
11 and salts of optical isomers. Some other names:

12 2-(methylamino)-propiofenone; alpha-(methylamino)propiofenone;

13 2-(methylamino)-1-phenylpropan-1-one;

14 alpha-N-methylaminopropiophenone; methylcathinone;

15 monomethylpropion; ephedrone; N-methylcathinone; AL-464; AL-422;

16 AL-463; and UR1432;

17 (6) (+/-)cis-4-methylaminorex; and

18 (+/-)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine;

19 and

20 (7) N,N-dimethylamphetamine;

21 N,N-alpha-trimethyl-benzeneethanamine; and

22 N,N-alpha-trimethylphenethylamine.

23 (f) Any controlled substance analogue to the extent  
24 intended for human consumption.

25 Schedule II

26 (a) Any of the following substances except those narcotic  
27 drugs listed in other schedules whether produced directly or

1 indirectly by extraction from substances of vegetable origin,  
2 independently by means of chemical synthesis, or by combination of  
3 extraction and chemical synthesis:

4 (1) Opium and opiate, and any salt, compound, derivative,  
5 or preparation of opium or opiate, excluding apomorphine,  
6 buprenorphine, thebaine-derived butorphanol, dextrorphan,  
7 nalbuphine, nalmefene, naloxone, and naltrexone and their  
8 salts, but including the following:

- 9 (i) Raw opium;  
10 (ii) Opium extracts;  
11 (iii) Opium fluid;  
12 (iv) Powdered opium;  
13 (v) Granulated opium;  
14 (vi) Tincture of opium;  
15 (vii) Codeine;  
16 (viii) Ethylmorphine;  
17 (ix) Etorphine hydrochloride;  
18 (x) Hydrocodone;  
19 (xi) Hydromorphone;  
20 (xii) Metopon;  
21 (xiii) Morphine;  
22 (xiv) Oxycodone;  
23 (xv) Oxymorphone;  
24 (xvi) Thebaine; and  
25 (xvii) Dihydroetorphine;  
26 (2) Any salt, compound, derivative, or preparation  
27 thereof which is chemically equivalent to or identical with any of

1 the substances referred to in subdivision (1) of this subdivision,  
2 except that these substances shall not include the isoquinoline  
3 alkaloids of opium;

4 (3) Opium poppy and poppy straw;

5 (4) Coca leaves and any salt, compound, derivative, or  
6 preparation of coca leaves, and any salt, compound, derivative,  
7 or preparation thereof which is chemically equivalent to or  
8 identical with any of these substances, including cocaine and  
9 its salts, optical isomers, and salts of optical isomers, except  
10 that the substances shall not include decocainized coca leaves or  
11 extractions which do not contain cocaine or ecgonine; and

12 (5) Concentrate of poppy straw, the crude extract of  
13 poppy straw in either liquid, solid, or powder form which contains  
14 the phenanthrene alkaloids of the opium poppy.

15 (b) Unless specifically excepted or unless in another  
16 schedule any of the following opiates, including their isomers,  
17 esters, ethers, salts, and salts of their isomers, esters, and  
18 ethers whenever the existence of such isomers, esters, ethers,  
19 and salts is possible within the specific chemical designation,  
20 dextrorphan excepted:

21 (1) Alphaprodine;

22 (2) Anileridine;

23 (3) Bezitramide;

24 (4) Diphenoxylate;

25 (5) Fentanyl;

26 (6) Isomethadone;

27 (7) Levomethorphan;

- 1 (8) Levorphanol;
- 2 (9) Metazocine;
- 3 (10) Methadone;
- 4 (11) Methadone-Intermediate,
- 5 4-cyano-2-dimethylamino-4,4-diphenyl butane;
- 6 (12) Moramide-intermediate,
- 7 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic acid;
- 8 (13) Pethidine or meperidine;
- 9 (14) Pethidine-Intermediate-A,
- 10 4-cyano-1-methyl-4-phenylpiperidine;
- 11 (15) Pethidine-Intermediate-B,
- 12 ethyl-4-phenylpiperidine-4-carboxylate;
- 13 (16) Pethidine-Intermediate-C,
- 14 1-methyl-4-phenylpiperidine-4-carboxylic acid;
- 15 (17) Phenazocine;
- 16 (18) Piminodine;
- 17 (19) Racemethorphan;
- 18 (20) Racemorphan;
- 19 (21) Dihydrocodeine;
- 20 (22) Bulk propoxyphene in nondosage forms;
- 21 (23) Sufentanil;
- 22 (24) Alfentanil;
- 23 (25) Levo-alpha-acetylmethadol which is also known as
- 24 levo-alpha-acetylmethadol, levomethadyl acetate, and LAAM;
- 25 (26) Carfentanil; and
- 26 (27) Remifentanil.
- 27 (c) Any material, compound, mixture, or preparation

1 which contains any quantity of the following substances having  
2 a potential for abuse associated with a stimulant effect on the  
3 central nervous system:

4 (1) Amphetamine, its salts, optical isomers, and salts of  
5 its optical isomers;

6 (2) Phenmetrazine and its salts;

7 (3) Methamphetamine, its salts, isomers, and salts of its  
8 isomers; and

9 (4) Methylphenidate.

10 (d) Any material, compound, mixture, or preparation  
11 which contains any quantity of the following substances having  
12 a potential for abuse associated with a depressant effect on the  
13 central nervous system, including their salts, isomers, and salts  
14 of isomers whenever the existence of such salts, isomers, and salts  
15 of isomers is possible within the specific chemical designations:

16 (1) Amobarbital;

17 (2) Secobarbital;

18 (3) Pentobarbital;

19 (4) Phencyclidine; and

20 (5) Glutethimide.

21 (e) Hallucinogenic substances known as:

22 (1) Nabilone. Another name for

23 nabilone: (+/-)-trans-3-(1,1-dimethylheptyl)-

24 6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H-

25 dibenzo(b,d)pyran-9-one.

26 (f) Unless specifically excepted or unless listed in  
27 another schedule, any material, compound, mixture, or preparation

1 which contains any quantity of the following substances:

2 (1) Immediate precursor to amphetamine and  
3 methamphetamine: Phenylacetone. Trade and other names shall  
4 include, but are not limited to: Phenyl-2-propanone; P2P; benzyl  
5 methyl ketone; and methyl benzyl ketone; or

6 (2) Immediate precursors to phencyclidine, PCP:

7 (i) 1-phenylcyclohexylamine; or

8 (ii) 1-piperidinocyclohexanecarbonitrile, PCC.

9 Schedule III

10 (a) Any material, compound, mixture, or preparation  
11 which contains any quantity of the following substances having  
12 a potential for abuse associated with a stimulant effect on the  
13 central nervous system, including their salts, isomers, whether  
14 optical, position, or geometric, and salts of such isomers whenever  
15 the existence of such salts, isomers, and salts of isomers is  
16 possible within the specific chemical designation:

17 (1) Benzphetamine;

18 (2) Chlorphentermine;

19 (3) Clortermine; and

20 (4) Phendimetrazine.

21 (b) Any material, compound, mixture, or preparation  
22 which contains any quantity of the following substances having  
23 a potential for abuse associated with a depressant effect on the  
24 central nervous system:

25 (1) Any substance which contains any quantity of a  
26 derivative of barbituric acid or any salt of a derivative of  
27 barbituric acid, except those substances which are specifically

1 listed in other schedules of this section;

2 (2) Chlorhexadol;

3 (3) Lysergic acid;

4 (4) Lysergic acid amide;

5 (5) Methyprylon;

6 (6) Sulfondiethylmethane;

7 (7) Sulfonethylmethane;

8 (8) Sulfonmethane;

9 (9) Nalorphine;

10 (10) Any compound, mixture, or preparation containing  
11 amobarbital, secobarbital, pentobarbital, or any salt thereof and  
12 one or more other active medicinal ingredients which are not listed  
13 in any schedule;

14 (11) Any suppository dosage form containing amobarbital,  
15 secobarbital, pentobarbital, or any salt of any of these drugs and  
16 approved by the Food and Drug Administration for marketing only as  
17 a suppository;

18 (12) Any drug product containing gamma-hydroxybutyric  
19 acid, including its salts, isomers, and salts of isomers, for which  
20 an application is approved under section 505 of the Federal Food,  
21 Drug, and Cosmetic Act, 21 U.S.C. 355, as such section existed on  
22 July 20, 2002;

23 (13) Ketamine, its salts, isomers, and  
24 salts of isomers. Some other names for ketamine:  
25 (+/-)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone; and

26 (14) Tiletamine and zolazepam or any salt thereof.  
27 Trade or other names for a tiletamine-zolazepam combination

1 product shall include, but are not limited to: telazol. Trade  
2 or other names for tiletamine shall include, but are not  
3 limited to: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone. Trade or  
4 other names for zolazepam shall include, but are not limited  
5 to: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-(3,4-e)  
6 (1,4)-diazepin-7(1H)-one, and flupyrazapon.

7 (c) Unless specifically excepted or unless listed in  
8 another schedule:

9 (1) Any material, compound, mixture, or preparation  
10 containing limited quantities of any of the following narcotic  
11 drugs, or any salts calculated as the free anhydrous base or  
12 alkaloid, in limited quantities as set forth below:

13 (i) Not more than one and eight-tenths grams of codeine  
14 per one hundred milliliters or not more than ninety milligrams per  
15 dosage unit, with an equal or greater quantity of an isoquinoline  
16 alkaloid of opium;

17 (ii) Not more than one and eight-tenths grams of codeine  
18 per one hundred milliliters or not more than ninety milligrams per  
19 dosage unit, with one or more active, nonnarcotic ingredients in  
20 recognized therapeutic amounts;

21 (iii) Not more than three hundred milligrams of  
22 dihydrocodeinone which is also known as hydrocodone per one hundred  
23 milliliters or not more than fifteen milligrams per dosage unit,  
24 with a fourfold or greater quantity of an isoquinoline alkaloid of  
25 opium;

26 (iv) Not more than three hundred milligrams of  
27 dihydrocodeinone which is also known as hydrocodone per one hundred

1 milliliters or not more than fifteen milligrams per dosage unit,  
2 with one or more active, nonnarcotic ingredients in recognized  
3 therapeutic amounts;

4 (v) Not more than one and eight-tenths grams of  
5 dihydrocodeine per one hundred milliliters or not more than ninety  
6 milligrams per dosage unit, with one or more active, nonnarcotic  
7 ingredients in recognized therapeutic amounts;

8 (vi) Not more than three hundred milligrams of  
9 ethylmorphine per one hundred milliliters or not more than fifteen  
10 milligrams per dosage unit, with one or more active, nonnarcotic  
11 ingredients in recognized therapeutic amounts;

12 (vii) Not more than five hundred milligrams of opium per  
13 one hundred milliliters or per one hundred grams, or not more than  
14 twenty-five milligrams per dosage unit, with one or more active,  
15 nonnarcotic ingredients in recognized therapeutic amounts; and

16 (viii) Not more than fifty milligrams of morphine per  
17 one hundred milliliters or per one hundred grams with one or more  
18 active, nonnarcotic ingredients in recognized therapeutic amounts;  
19 and

20 (2) Any material, compound, mixture, or preparation  
21 containing any of the following narcotic drug or its salts, as  
22 set forth below:

23 (i) Buprenorphine.

24 (d) Unless contained on the administration's list of  
25 exempt anabolic steroids as the list existed on June 1, 2007,  
26 any anabolic steroid, which shall include any material, compound,  
27 mixture, or preparation containing any quantity of the following

1 substances, including its salts, isomers, and salts of isomers  
2 whenever the existence of such salts of isomers is possible within  
3 the specific chemical designation:

- 4 (1) Boldenone;
- 5 (2) Chlorotestosterone (4-chlortestosterone);
- 6 (3) Clostebol;
- 7 (4) Dehydrochlormethyltestosterone;
- 8 (5) Dihydrotestosterone (4-dihydrotestosterone);
- 9 (6) Drostanolone;
- 10 (7) Ethylestrenol;
- 11 (8) Fluoxymesterone;
- 12 (9) Formebolone (formebolone);
- 13 (10) Mesterolone;
- 14 (11) Methandienone;
- 15 (12) Methandranone;
- 16 (13) Methandriol;
- 17 (14) Methandrostenolone;
- 18 (15) Methenolone;
- 19 (16) Methyltestosterone;
- 20 (17) Mibolerone;
- 21 (18) Nandrolone;
- 22 (19) Norethandrolone;
- 23 (20) Oxandrolone;
- 24 (21) Oxymesterone;
- 25 (22) Oxymetholone;
- 26 (23) Stanolone;
- 27 (24) Stanozolol;

- 1                   (25) Testolactone;  
2                   (26) Testosterone;  
3                   (27) Trenbolone; and  
4                   (28) Any salt, ester, or isomer of a drug or substance  
5 described or listed in this subdivision if the salt, ester, or  
6 isomer promotes muscle growth.

7                   (e) Hallucinogenic substances known as:

- 8                   (1) Dronabinol, synthetic, in sesame oil and encapsulated  
9 in a soft gelatin capsule in a Food and Drug Administration  
10 approved drug product. Some other names for dronabinol are  
11 (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo  
12 (b,d)pyran-1-ol or (-)-delta-9-(trans)-tetrahydrocannabinol.

13                   Schedule IV

14                   (a) Any material, compound, mixture, or preparation which  
15 contains any quantity of the following substances, including their  
16 salts, isomers, and salts of isomers whenever the existence of  
17 such salts, isomers, and salts of isomers is possible within the  
18 specific chemical designation:

- 19                   (1) Barbital;  
20                   (2) Chloral betaine;  
21                   (3) Chloral hydrate;  
22                   (4) Chlordiazepoxide, but not including librax  
23 (chlordiazepoxide hydrochloride and clindinium bromide) or menrium  
24 (chlordiazepoxide and water soluble esterified estrogens);  
25                   (5) Clonazepam;  
26                   (6) Clorazepate;  
27                   (7) Diazepam;

- 1 (8) Ethchlorvynol;
- 2 (9) Ethinamate;
- 3 (10) Flurazepam;
- 4 (11) Mebutamate;
- 5 (12) Meprobamate;
- 6 (13) Methohexital;
- 7 (14) Methylphenobarbital;
- 8 (15) Oxazepam;
- 9 (16) Paraldehyde;
- 10 (17) Petrichloral;
- 11 (18) Phenobarbital;
- 12 (19) Prazepam;
- 13 (20) Alprazolam;
- 14 (21) Bromazepam;
- 15 (22) Camazepam;
- 16 (23) Clobazam;
- 17 (24) Clotiazepam;
- 18 (25) Cloxazolam;
- 19 (26) Delorazepam;
- 20 (27) Estazolam;
- 21 (28) Ethyl loflazepate;
- 22 (29) Fludiazepam;
- 23 (30) Flunitrazepam;
- 24 (31) Halazepam;
- 25 (32) Haloxazolam;
- 26 (33) Ketazolam;
- 27 (34) Loprazolam;

- 1 (35) Lorazepam;
- 2 (36) Lormetazepam;
- 3 (37) Medazepam;
- 4 (38) Nimetazepam;
- 5 (39) Nitrazepam;
- 6 (40) Nordiazepam;
- 7 (41) Oxazolam;
- 8 (42) Pinazepam;
- 9 (43) Temazepam;
- 10 (44) Tetrazepam;
- 11 (45) Triazolam;
- 12 (46) Midazolam;
- 13 (47) Quazepam;
- 14 (48) Zolpidem;
- 15 (49) Dichloralphenazone; and
- 16 (50) Zaleplon.

17 (b) Any material, compound, mixture, or preparation which  
18 contains any quantity of the following substance, including its  
19 salts, isomers, whether optical, position, or geometric, and salts  
20 of such isomers, whenever the existence of such salts, isomers, and  
21 salts of isomers is possible: Fenfluramine.

22 (c) Unless specifically excepted or unless listed in  
23 another schedule, any material, compound, mixture, or preparation  
24 which contains any quantity of the following substances having a  
25 stimulant effect on the central nervous system, including their  
26 salts, isomers, whether optical, position, or geometric, and salts  
27 of such isomers whenever the existence of such salts, isomers,

1 and salts of isomers is possible within the specific chemical  
2 designation:

3 (1) Diethylpropion;

4 (2) Phentermine;

5 (3) Pemoline, including organometallic complexes and  
6 chelates thereof;

7 (4) Mazindol;

8 (5) Pipradrol;

9 (6) SPA, ((-)-1-dimethylamino- 1,2-diphenylethane);

10 (7) Cathine. Another name for cathine is  
11 ((+)-norpseudoephedrine);

12 (8) Fencamfamin;

13 (9) Fenproporex;

14 (10) Mefenorex;

15 (11) Modafinil; and

16 (12) Sibutramine.

17 (d) Unless specifically excepted or unless listed in  
18 another schedule, any material, compound, mixture, or preparation  
19 which contains any quantity of the following narcotic drugs, or  
20 their salts or isomers calculated as the free anhydrous base or  
21 alkaloid, in limited quantities as set forth below:

22 (1) Propoxyphene in manufactured dosage forms; and

23 (2) Not more than one milligram of difenoxin and not less  
24 than twenty-five micrograms of atropine sulfate per dosage unit.

25 (e) Unless specifically excepted or unless listed in  
26 another schedule, any material, compound, mixture, or preparation  
27 which contains any quantity of the following substance, including

1 its salts: Pentazocine.

2 (f) Unless specifically excepted or unless listed in  
3 another schedule, any material, compound, mixture, or preparation  
4 which contains any quantity of the following substance, including  
5 its salts, isomers, and salts of such isomers: Butorphanol.

6 (g) (1) Unless specifically excepted or unless listed in  
7 another schedule, any material, compound, mixture, or preparation  
8 which contains any quantity of the following substance, including  
9 its salts, optical isomers, and salts of such optical isomers:  
10 Ephedrine.

11 (2) The following drug products containing ephedrine,  
12 its salts, optical isomers, and salts of such optical isomers  
13 are excepted from subdivision (g) (1) of Schedule IV if they may  
14 lawfully be sold over the counter without a prescription under  
15 the Federal Food, Drug, and Cosmetic Act, as the act existed on  
16 September 1, 2001; are labeled and marketed in a manner consistent  
17 with the pertinent OTC Tentative Final or Final Monograph; are  
18 manufactured and distributed for legitimate medicinal use in a  
19 manner that reduces or eliminates the likelihood of abuse; and  
20 are not marketed, advertised, or represented in any manner for the  
21 indication of stimulation, mental alertness, euphoria, ecstasy, a  
22 buzz or high, heightened sexual performance, or increased muscle  
23 mass:

24 (A) Primatene Tablets;

25 (B) Bronkaid Dual Action Caplets; and

26 (C) Pazo Hemorrhoidal Ointment.

27 (3) Food and dietary supplements described in 21 U.S.C.

1 321, as such section existed on September 1, 2001, containing  
2 ephedrine, including its salts, optical isomers, and salts of such  
3 optical isomers, are excepted from subdivision (g) (1) of Schedule  
4 IV if:

5 (A) They are labeled in a manner consistent with section  
6 28-448 and bear the statements: "This statement has not been  
7 evaluated by the Food and Drug Administration. This product is not  
8 intended to diagnose, treat, cure, or prevent any disease.";

9 (B) Any dosage form of the food or dietary supplements  
10 (i) does not contain any hydrochloride or sulfate salts of  
11 ephedrine alkaloids, (ii) does not contain more than twenty-five  
12 milligrams of ephedrine alkaloids, and (iii) does not contain  
13 ephedrine alkaloids in excess of five percent of the total capsule  
14 weight;

15 (C) They are not marketed, advertised, or represented in  
16 any manner for the indication of stimulation, mental alertness,  
17 euphoria, ecstasy, a buzz or high, heightened sexual performance,  
18 or increased muscle mass; and

19 (D) Analysis of the product is provided to the department  
20 to ensure that the product meets the requirements of subdivision  
21 (g) (3) (B) of Schedule IV.

22 Schedule V

23 (a) Any compound, mixture, or preparation containing any  
24 of the following limited quantities of narcotic drugs or salts  
25 calculated as the free anhydrous base or alkaloid, which shall  
26 include one or more nonnarcotic active medicinal ingredients in  
27 sufficient proportion to confer upon the compound, mixture, or

1 preparation valuable medicinal qualities other than those possessed  
2 by the narcotic drug alone:

3 (1) Not more than two hundred milligrams of codeine per  
4 one hundred milliliters or per one hundred grams;

5 (2) Not more than one hundred milligrams of  
6 dihydrocodeine per one hundred milliliters or per one hundred  
7 grams;

8 (3) Not more than one hundred milligrams of ethylmorphine  
9 per one hundred milliliters or per one hundred grams;

10 (4) Not more than two and five-tenths milligrams of  
11 diphenoxylate and not less than twenty-five micrograms of atropine  
12 sulfate per dosage unit;

13 (5) Not more than one hundred milligrams of opium per one  
14 hundred milliliters or per one hundred grams; and

15 (6) Not more than five-tenths milligram of difenoxin and  
16 not less than twenty-five micrograms of atropine sulfate per dosage  
17 unit.

18 (b) Unless specifically exempted or excluded or unless  
19 listed in another schedule, any material, compound, mixture, or  
20 preparation which contains any quantity of the following substances  
21 having a stimulant effect on the central nervous system, including  
22 its salts, isomers, and salts of isomers: Pyrovalerone.

23 2. On page 7, line 25, strike "and"; and in line 26  
24 after the last comma insert "and section 28-405, Revised Statutes  
25 Supplement, 2007,".

26 3. Renumber the remaining sections accordingly.